Cephalosporin Drugs Market By Generation (First Generation, Second Generation, Third Generation, Fourth Generation, Fifth Generation), By Route of Administration (Injection, Oral), By Application (Respiratory Tract, Skin Infection, Ear Infection, Urinary Tract Infection, Sexually Transmitted Infection), and By Region - Trends, Analysis and Forecast till 2034

Cephalosporin Drugs Market was valued at USD 19.6 Billion in 2024 and is projected to grow at a CAGR of 8.20% to reach USD 40.4 Billion by 2034.

Acremonium (formerly known as Cephalosporium), a mold, is the source of a broad class of medicines known as cephalosporins. Similar to how penicillin’s function, cephalosporins are bactericidal drugs. The enzymes that produce peptidoglycan, a crucial part of the bacterial cell wall, are bound to by them and prevent their activity. They are efficient against a variety of bacteria, which is why they are known as broad-spectrum antibiotics.

According to National Institute of Health, an estimated 10 million people worldwide contracted tuberculosis (TB) in 2020, with eight countries accounting for two-thirds of all cases in 2021, with India leading the list, followed by China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and Soudan. The growth of the Cephalosporin Drug Market can boost by the rising cases of respiratory tract infections such as TB. The market growth was significantly impacted by COVID-19 as well because of the rise in household and physician prescriptions for antibiotics during the pandemic. Furthermore, increasing incidences of bacterial skin infections specifically resource poor region is also expected to propel the target market growth, for instance according to National Institute of Health skin conditions contributed 1.79% to the total burden of disease measured in DALYs across 306 diseases and injuries.

                     For More Report Details, Download Free Sample PDF

Increase in research and development activity

Increased research and development efforts targeted at launching novel combinations and extending the product line to encompass more infectious disease treatments will eventually lead to growth in the Cephalosporin Drugs Market.

For instance, in June 2021, according to BIOVERSYS, CARB-X announced US$ 4.35 million in non-dilutive funding for BioVersys AG for a privately held clinical trials. BioVersys AG focuses on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation.

Strategic development of new product

The market for cephalosporin drugs may expand as a result of companies employing their resources to create products in a strategic manner. A strategic launch can be advantageous to target a sizable market niche and aid in the expansion of the cephalosporin industry.

For instance, in September 2021, Lincoln Pharmaceuticals Limited, released cephalosporin-based medications with the purchase of the facility in Mehsana, Gujarat, and would devote Rs. 30 crores on upgrading and expanding the cephalosporin plant's capacity.

Restrains of Cephalosporin Drugs Market:

Unfavorable development conditions due to various barriers

Having dependable and potent antibiotic medications will be more crucial than ever as more and more patients contract difficult-to-treat, multi-drug resistance diseases. For pharmaceutical corporations, investing in antibiotics is a less appealing business venture due to limitation in science, regulations, and finances.

For instance, according to ACS Publication Article Titled “Research and Development of Antibiotics: The Next Battleground" shows how a perfect combination of scientific difficulties, regulatory uncertainties, challenging markets, and industry consolidation has hampered antibiotic market.

Cephalosporin Drugs Market is segmented based on Generation, Route of Administration, Application and Region.

Generation Insight

On the basis of Generation, Cephalosporin Drugs Market is segmented into First Generation, Second Generation, Third Generation, Fourth Generation, and Fifth Generation. Third Generation segment is expected to dominate the target market growth as these are used for treatment of gram-negative bacillary meningitis, serious infections of Enterobacteriaceae, otitis media, pyelonephritis, skin & soft tissue infections, Lyme disease, and gonorrhea.

Route of Administration Insights

On the basis of Route of Administration, Cephalosporin Drugs Market is segmented into Injection, Oral. Injections are expected to dominate the target market growth as injections provide a direct route for delivering Cephalosporin drugs into the bloodstream. This ensures quick absorption and distribution of the medication throughout the body. 

Application Insights

On the basis of Application, Cephalosporin Drugs Market is segmented into Respiratory Tract, Skin Infection, Ear Infection, Urinary Tract Infection, and Sexually Transmitted Infection. Respiratory tract is expected to dominate target market growth due to rise in number of upper respiratory tract infections.

Regional Insights:

On the basis of region, the Cephalosporin Drugs Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America has been witnessing a positive growth for cephalosporin market throughout the forecasted period due to the growing prevalence of diseases and rising healthcare expenditure. Furthermore Asia Pacific serves as largest market with owing many future opportunities for growth due to high population density and rising prevalence of diseases.    

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Cephalosporin Drugs Market report based on Generation, Route of Administration, Application and Region:

Cephalosporin Drugs Market, By Generation:

• First Generation
• Second Generation
• Third Generation
• Fourth Generation
• Fifth Generation

Cephalosporin Drugs Market, By Route of Administration:

• Oral
• Injection

Cephalosporin Drugs Market, By Application:

• Respiratory Tract
• Skin Infection
• Ear Infection
• Urinary Tract Infection
• Sexually Transmitted Infection

Cephalosporin Drugs Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

The key players operating the Cephalosporin Drugs Market includes, Allergan Plc., Bristol-Myers Squibb Company, Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Lupin Limited, Merck & Co. Inc., Novartis International AG (Sandoz), Pfizer, Inc.  Sanofi, Inc. and Teva Pharmaceutical Industries, Ltd.

• In December 2022, "Shionogi & Co.", Ltd., announced that Taiwan Shionogi & Co., Ltd., a subsidiary of Shionogi, filed a New Drug Application (NDA) for "cefiderocol", a new siderophore cephalosporin antibacterial drug, to the TFDA (Taiwan Food and Drug Administration) for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options, and this application has been accepted for review by TFDA.
• In September 2021, “Lincoln Pharma” has set aside Rs 30 crore for the expansion of its Cephalosporin product portfolio and will shortly introduce them in India. The pharmaceutical business has plans to launch its Cephalosporin product portfolio soon.
• In February 2021 “Sandoz” announces agreement to acquire “GSK’s” cephalosporin antibiotics business, reinforcing its leading global position in antibiotics The agreement includes the global rights to three established brands (Zinnat®, Zinacef® and Fortum®) in more than 100 markets. It excludes the rights in the US, Australia and Germany to certain of those brands, which were previously divested by “GSK”, and in India, Pakistan, Egypt, Japan (to certain of the brands) and China, which will be retained by GSK.

• Allergan Plc.
• Bristol-Myers Squibb Company
• Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Lupin Limited
• Merck & Co. Inc.
• Novartis International AG (Sandoz)
• Pfizer, Inc.
• Sanofi, Inc.
• Teva Pharmaceutical Industries, Ltd.